BACK<<     
 
 
Aeolus Pharmaceuticals, Inc.
  SYMBOL: ( OTCBB: AOLS)
 
John L. McManus   Brian J. Day
CEO   Chief Scientific Officer
 
Interviewed On: Fri, Jul 13 2007
  Interview Formats: Real Audio
Windows Media
  Other Options:
   
 
 
 
 
   INSTITUTIONAL OWNERSHIP / ANALYST COVERAGE
 

Institutional Investors:

  • BVF, Inc.
  • California Public Employees Retirement System
  • Perceptive Advisors, LLC
 
   DISCLAIMER
 

 Aeolus Pharmaceuticals Inc., five thousand dollars per month in cash and two hundred fifty thousand warrants

 
   OTHER INFORMATION
 

Top Competitors:

  • Cleveland Biolabs
  • Novartis AG
  • Sanofi-Aventis
 
   COMPANY PROFILE  
 

Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118 million, to efficiently develop the compound for use in oncology.

 
 
   COMPANY PRESS RELEASE
 
 
01/02/13
-Aeolus Pharmaceuticals Announces Fiscal Year 2012 Results 
 
09/06/12
-Aeolus Pharmaceuticals Provides Positive Update on FDA Meeting 
 
08/14/12
-Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2012 Financial Results 
 
07/30/12
-Aeolus Pharmaceuticals Announces AEOL 10150 Diminishes Oxidative Stress and Nerve Damage Following Exposure to Nerve Agent 
 
06/01/12
-Aeolus Pharmaceuticals Announces AEOL 10150 Reduces Lung Damage After Neupogen(R) Treatment Following Radiation Exposure 
 
05/15/12
-Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2012 Financial Results 
 
04/16/12
-BARDA Exercises $9.1 Million in Contract Options With Aeolus 
 
04/09/12
-BARDA Delivers Notice of Intent to Exercise Additional Contract Options With Aeolus Worth $9.1 Million 
 
04/05/12
-Aeolus Pharmaceuticals Announces Date and Time for Barda Contract and Corporate Update Conference Call 
 
03/13/12
-Aeolus to Present at Roth Capital Partners' 24th Annual Growth Stock Conference 
 
02/15/12
-Aeolus Announces No-Cost Extension and Modification of Barda Contract Fully Valued at $118 Million to Develop Treatment for Lung A 
 
02/13/12
-Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results 
 
02/08/12
-Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis 
 
02/07/12
-Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model Published in the Journal of Neurobiology of Disease 
 
01/17/12
-Aeolus to Present at the Noble Financial Capital Markets' 8th Annual Equity Conference 
 
12/28/11
-Aeolus Pharmaceuticals Announces Fiscal Year 2011 Results 
 
12/07/11
-Aeolus to Present at the 22nd Annual Oppenheimer Healthcare Conference 
 
11/09/11
-Aeolus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference 
 
11/01/11
-Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150 and Neupogen(R) as Combination Therapy for Treatment of 
 
10/24/11
-Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure 
 
10/24/11
-Aeolus to Present at the 10th Annual BIO Investor Forum 
 
10/10/11
-Aeolus Pharmaceuticals Announces $12.7 Million NIH Counteract Grant Award to Continue Development of AEOL 10150  
 
10/05/11
-Roth Capital Initiates Equity Research Analyst Coverage on Aeolus 
 
09/23/11
-Aeolus Pharmaceuticals Files Request for Orphan Drug Designation of AEOL 10150 for Mitigation, and/or Treatment of Delayed Effects 
 
09/06/11
-Aeolus to Present at Stifel Nicolaus' Annual Healthcare Conference 
 
09/01/11
-Aeolus Pharmaceuticals' Announces Presentation of AEOL10150 Data at the 14th International Congress of Radiation Research 
 
08/29/11
-Ladenburg Thalmann Initiates Equity Research Analyst Coverage on Aeolus 
 
06/06/11
-Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 
   KEY PRODUCTS / SERVICES  
 

Aeolus has two programs underway for the development of their second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson’s disease.   These programs are being funded, in part, by private foundations and government grants.

 
 
   
   
 
Copyright © 2001-2017. All Rights Reserved. Disclaimer | Privacy Policy